secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001628280-26-030866
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeOne Q1 2026: revenue $1.5B (+35%), BRUKINSA $1.1B (+38%), diluted EPS $1.96/$3.24
--------------------------------------------------------------------------------

- Total global revenue $1.5B for Q1 2026, up 35% from prior year.
- BRUKINSA global revenue $1.1B, up 38% YoY, maintains BTKi leadership.
- GAAP diluted EPS $1.96 (vs $0.01); non-GAAP diluted EPS $3.24 (vs $1.22).
- GAAP net income $227M (vs $1.3M); adjusted net income $375M (vs $136M).
- Free cash flow $161M, turnaround from negative $12M in prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000162828026030866/0001628280-26-030866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000162828026030866/bgne-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-030866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer